ProfileGDS5678 / 1427130_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 19% 18% 19% 19% 17% 26% 19% 19% 17% 19% 19% 18% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4944320
GSM967853U87-EV human glioblastoma xenograft - Control 22.4515919
GSM967854U87-EV human glioblastoma xenograft - Control 32.4430718
GSM967855U87-EV human glioblastoma xenograft - Control 42.4163619
GSM967856U87-EV human glioblastoma xenograft - Control 52.4067619
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4785717
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6363626
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4333619
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4286419
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4146917
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4355319
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4303519
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4388418
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.443119